ZOM Valuation
Zomedica Corp
$
0.000
- Overview
- Forecast
- Valuation
- Earnings
ZOM Relative Valuation
ZOM's fair value is calculated using relative valuation, based on historical P/E and P/S ranges and their premiums/discounts relative to a competitor average, adjusted by weights. If the market price exceeds this fair value range, ZOM is overvalued; if below, it's undervalued.
Historical Valuation
Trailing
Forward
P/E
P/E
EV/EBITDA
EV/EBIT
P/S
P/OCF
P/FCF
1Y
3Y
5Y
Trailing
Forward
0.47
P/B
Median3y
0.71
Median5y
2.18
-28.99
FCF Yield
Median3y
-15.47
Median5y
-12.06
Competitors Valuation Multiple
The average P/S ratio for ZOM's competitors is 34.46, providing a benchmark for relative valuation. Zomedica Corp Corp (ZOM) exhibits a P/S ratio of , which is -100.00% above the industry average. Given its robust revenue growth of 10.24%, this premium appears unsustainable.
People Also Watch
GATE
Marblegate Acquisition Corp
0
USD
+45.60%
DTI
Drilling Tools International Corp
2.310
USD
-0.43%
GEOS
Geospace Technologies Corp
11.580
USD
+3.67%
NYMTL
New York Mortgage Trust Inc
21.807
USD
+0.03%
TOUR
Tuniu Corp
0.868
USD
-2.36%
BDTX
Black Diamond Therapeutics Inc
3.190
USD
0.00%
TLYS
Tillys Inc
1.630
USD
+9.40%
VGAS
Verde Clean Fuels Inc
3.230
USD
-1.52%
BKTI
BK Technologies Corp
39.920
USD
-1.92%
ANRO
Alto Neuroscience Inc
3.070
USD
+9.64%
FAQ
Is Zomedica Corp (ZOM) currently overvalued or undervalued?
Zomedica Corp (ZOM) is now in the Fair zone, suggesting that its current forward PS ratio of NaN is considered Fairly compared with the five-year average of -18.41. The fair price of Zomedica Corp (ZOM) is between to according to relative valuation methord.
What is Zomedica Corp (ZOM) fair value?
How does ZOM's valuation metrics compare to the industry average?
What is the current P/B ratio for Zomedica Corp (ZOM) as of Jul 24 2025?
What is the current FCF Yield for Zomedica Corp (ZOM) as of Jul 24 2025?
What is the current Forward P/E ratio for Zomedica Corp (ZOM) as of Jul 24 2025?